A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions

Pancreatic Cancer

Interventions

DRUG

AK112

Following a predefined dose and date.

DRUG

AK130

Following a predefined dose and date.

Trial Locations (2)

Zhongshan Hospital Affiliated to Fudan University, Shanghai

Tianjin Medical University Cancer Institute and Hospital, Tianjin